Year |
Citation |
Score |
2020 |
Holshouser S, Cafiero R, Robinson M, Kirkpatrick J, Casero RA, Hyacinth HI, Woster PM. Epigenetic Reexpression of Hemoglobin F Using Reversible LSD1 Inhibitors: Potential Therapies for Sickle Cell Disease. Acs Omega. 5: 14750-14758. PMID 32596612 DOI: 10.1021/acsomega.0c01585 |
0.723 |
|
2020 |
Sierra JC, Piazuelo MB, Luis PB, Barry DP, Allaman MM, Asim M, Sebrell TA, Finley JL, Rose KL, Hill S, Holshouser SL, Casero RA, Cleveland JL, Woster PM, Schey KL, et al. Spermine oxidase mediates Helicobacter pylori-induced gastric inflammation, DNA damage, and carcinogenic signaling. Oncogene. PMID 32350444 DOI: 10.1038/S41388-020-1304-6 |
0.481 |
|
2019 |
Holshouser S, Dunworth M, Murray-Stewart T, Peterson YK, Burger P, Kirkpatrick J, Chen HH, Casero RA, Woster PM. Dual inhibitors of LSD1 and spermine oxidase. Medchemcomm. 10: 778-790. PMID 31191868 DOI: 10.1039/C8Md00610E |
0.76 |
|
2018 |
Nowotarski SL, Pachaiyappan B, Holshouser SL, Kutz CJ, Li Y, Huang Y, Sharma SK, Casero RA, Woster PM. Corrigendum to "Structure-activity study for (bis)ureidopropyl- and (bis)thioureidopropyldiamine LSD1 inhibitors with 3-5-3 and 3-6-3 carbon backbone architectures" [Bioorg. Med. Chem. 23 (2015) 1601-1612]. Bioorganic & Medicinal Chemistry. PMID 29859749 DOI: 10.1016/J.Bmc.2018.05.032 |
0.674 |
|
2015 |
Nowotarski SL, Pachaiyappan B, Holshouser SL, Kutz CJ, Li Y, Huang Y, Sharma SK, Casero RA, Woster PM. Structure-activity study for (bis)ureidopropyl- and (bis)thioureidopropyldiamine LSD1 inhibitors with 3-5-3 and 3-6-3 carbon backbone architectures. Bioorganic & Medicinal Chemistry. 23: 1601-12. PMID 25725609 DOI: 10.1016/J.Bmc.2015.01.049 |
0.695 |
|
2015 |
Cafiero RM, Holshouser S, Kutz C, Kanter J, Woster P. Novel Epigenetic Modulators That Promote Fetal Hemoglobin Production for the Prevention of Sickle Cell Disease Related Complications Blood. 126: 973-973. DOI: 10.1182/Blood.V126.23.973.973 |
0.702 |
|
2014 |
Kutz CJ, Holshouser SL, Marrow EA, Woster PM. 3,5-Diamino-1,2,4-triazoles as a novel scaffold for potent, reversible LSD1 (KDM1A) inhibitors. Medchemcomm. 5: 1863-1870. PMID 25580204 DOI: 10.1039/C4Md00283K |
0.742 |
|
2014 |
Kutz CJ, Holshouser SL, Marrow EA, Woster PM. 3,5-Diamino-1,2,4-triazoles as a novel scaffold for potent, reversible LSD1 (KDM1A) inhibitors Medchemcomm. 5: 1863-1870. DOI: 10.1039/c4md00283k |
0.729 |
|
Show low-probability matches. |